FibroBiologics completes CGMP manufacturing of CYWC628 for diabetic foot ulcer trial

FibroBiologics, Inc. +3.76%

FibroBiologics, Inc.

FBLG

1.38

+3.76%

  • FibroBiologics completed first batch manufacturing of CYWC628 to support a first-in-human Phase 1/2 clinical trial in diabetic foot ulcer patients planned for H1 2026.
  • Trial results have not been presented; readout will occur in future once study is underway.
  • CYWC628 drug product was produced under FDA CGMP; release is pending completion of required safety and quality testing.
  • Manufacturing milestone positions program to enter clinic, supporting FibroBiologics strategy to advance fibroblast-based therapies in chronic disease.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fibrobiologics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603311615PRIMZONEFULLFEED9681143) on March 31, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.